Diabetic patients on Rutherford's stage 5 is the best indication of stem cell therapy in peripheral artery disease: A retrospective study on 367 patients

Lehalle, Bertrand; Philippé, Jan; Stoltz, Jean‐François

doi:10.1016/j.jocit.2018.09.005

Cited by 2 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Arterial revascularization has been recognized a condition necessary for the obtainment of a positive clinical outcome. However, in a retrospective trial, Lehalle et al demonstrated that revascularization was not sufficient for wound healing in diabetic patients (143). Moreover, the same study also observed that 20% of wounds healed of diabetic patients were going to develop new ulcers after 3 years.…”

Section: Clinical Trials In No-option Patientsmentioning

confidence: 98%

“…Accordingly, a retrospective study on 367 patients revealed that Rutherford's stage 5 was the best indication for autologous cell therapy in PAD; 50% of Rutherford's stage 6 patients who initially had major tissue loss, overstepping metatarsus phalangeal level (Rutherford's stage 6), all went through a major amputation, suggesting that treatment was performed in a too advanced stage in some patients (143).…”

Section: Clinical Trials In No-option Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Autologous cell therapy in diabetes‑associated critical limb ischemia: From basic studies to clinical outcomes (Review)

Magenta

Florio

Ruggeri³

et al. 2021

Int J Mol Med

View full text Add to dashboard Cite

Cell therapy is becoming an attractive alternative for the treatment of patients with no-option critical limb ischemia (CLI). The main benefits of cell therapy are the induction of therapeutic angiogenesis and neovascularization that lead to an increase in blood flow in the ischemic limb and tissue regeneration in non-healing cutaneous trophic lesions. In the present review, the current state of the art of strategies in the cell therapy field are summarized, focusing on intra-operative autologous cell concentrates in diabetic patients with CLI, examining different sources of cell concentrates and their mechanisms of action. The present study underlined the detrimental effects of the diabetic condition on different sources of autologous cells used in cell therapy, and also in delaying wound healing capacity. Moreover, relevant clinical trials and critical issues arising from cell therapy trials are discussed. Finally, the new concept of cell therapy as an adjuvant therapy to increase wound healing in revascularized diabetic patients is introduced. Contents 1. Introduction 2. Cell therapy: Unfractioned mixed cell population concentrate or pure stem/progenitor cell concentrate 3. Diabetes impairs the angiogenic and regenerative capacity of autologous cell therapy 4. Clinical trials in no-option patients 5. Conclusions and future perspectives

show abstract

Section: Clinical Trials In No-option Patientsmentioning

confidence: 98%

Section: Clinical Trials In No-option Patientsmentioning

confidence: 99%

Autologous cell therapy in diabetes‑associated critical limb ischemia: From basic studies to clinical outcomes (Review)

Magenta

Florio

Ruggeri³

et al. 2021

Int J Mol Med

View full text Add to dashboard Cite

show abstract

“…These outcomes support previously mentioned data that diabetes has a deleterious impact on BMMNC treatment for peripheral ischemia. Moreover, a retrospective study of 367 patients revealed that Rutherford's stage 5 was the best indication for ACT in patients with PAD [ 56 ]. Fifty percent of Rutherford's stage 6 patients who initially suffered from a major tissue loss, overstepping metatarsus phalangeal level (Rutherford's stage 6), all went through a major amputation, implying that treatment was performed in some patients at a too advanced stage…”

Section: Significant Randomized Controlled Trialsmentioning

confidence: 99%

Cell Therapy of Severe Ischemia in People with Diabetic Foot Ulcers—Do We Have Enough Evidence?

Dubský,

Husáková,

Sojáková

et al. 2023

Mol Diagn Ther

View full text Add to dashboard Cite

This current opinion article critically evaluates the efficacy of autologous cell therapy (ACT) for chronic limb-threatening ischemia (CLTI), especially in people with diabetes who are not candidates for standard revascularization. This treatment approach has been used in ‘no-option’ CLTI in the last two decades and more than 1700 patients have received ACT worldwide. Here we analyze the level of published evidence of ACT as well as our experience with this treatment method. Many studies have shown that ACT is safe and an effective method for patients with the most severe lower limb ischemia. However, some trials did not show any benefit of ACT, and there is some heterogeneity in the types of injected cells, route of administration and assessed endpoints. Nevertheless, we believe that ACT plays an important role in a comprehensive treatment of patients with diabetic foot and severe ischemia.

show abstract

Diabetic patients on Rutherford's stage 5 is the best indication of stem cell therapy in peripheral artery disease: A retrospective study on 367 patients

Cited by 2 publications

References 18 publications

Autologous cell therapy in diabetes‑associated critical limb ischemia: From basic studies to clinical outcomes (Review)

Autologous cell therapy in diabetes‑associated critical limb ischemia: From basic studies to clinical outcomes (Review)

Cell Therapy of Severe Ischemia in People with Diabetic Foot Ulcers—Do We Have Enough Evidence?

Contact Info

Product

Resources

About